Abstract 685TiP
Background
Targeted Radiopharmaceutical Therapy (RPT) with [177Lu]Lu-edotreotide is being explored as treatment option for patients with relapsed/refractory somatostatin receptor (SSTR)-positive tumors, including neuroendocrine tumors, CNS-tumors, lymphoma, rhabdomyosarcoma, peripheral primitive neuroectodermal tumors and gastrointestinal sarcoma tumors.
Trial design
KinLET is an open-label, multicenter, phase I trial aiming to determine the appropriate dose based on the safety profile and the pharmacokinetics (PK) of [177Lu]Lu-edotreotide targeted RPT in pediatric patients with SSTR-positive tumors. Further objectives include the assessment of preliminary anti-tumor activity by tumor type, safety and dosimetry evaluations. Up to 100 MBq/kg or 7.5 GBq/75 kg for each treatment cycle will be studied. Dosage of [177Lu]Lu-edotreotide will be adjusted based on the patient's weight as well as dosimetry in a subset of patients and applied sequentially in each cohort to not exceed a total absorbed dose of 23 Gy and 2 Gy to kidneys and bone marrow, respectively. [177Lu]Lu-edotreotide dosimetry is planned to be evaluated by single-photon emission computed tomography/low dose computed tomography; whole body planar imaging and blood radioactivity measurements at specific intervals, along with safety and preliminary efficacy parameters. It is planned to include at least 20 participants in three sequential age cohorts: (1) ≥12 to <18 years old; (2) ≥6 years to <12 years old; (3) ≥2 to <6 years old (minimum of six participants in each age cohort). The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1 of the previous cohort. Treatment will comprise two to six [177Lu]Lu-edotreotide treatment cycles every eight weeks. Tumor assessment and follow-up evaluation by anatomical and functional imaging is performed within the treatment period and the first two years of the five-year follow-up. Due to the rare incidence of SSTR-positive tumors in pediatric patients, patient recruitment is a key element in this trial.
Clinical trial identification
Editorial acknowledgement
Margret I. Moré.
Legal entity responsible for the study
ITM Solucin GmbH.
Funding
ITM Solucin GmbH.
Disclosure
S. Melnyk, T. Thevenet: Financial Interests, Institutional, Full or part-time Employment: ITM Isotope Technologies Munich SE. A. Rotger: Financial Interests, Institutional, Financially compensated role: ITM Isotope Technologies Munich SE. All other authors have declared no conflicts of interest.
Resources from the same session
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01